Eurofins Scientific ERF.PA · EUR
Health Care · Life Sciences Tools & Services · Euronext Paris · 🇫🇷 France
87.24
-1.58%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Eurofins Scientific
Its shares trade on Euronext Paris under the ticker ERF.PA. It has been listed since 24 October 1997. In the fiscal year to 31 December 2025, it reported revenue of €7.30bn and net income of €475.0m. At that date it held total assets of €10.98bn and shareholders' equity of €3.54bn.
Eurofins Scientific SE engages in the bio-analytical testing of food, environment, and pharmaceuticals products. The firm joins a part of international group of laboratories providing a range of analytical testing services to the pharmaceutical, food, environmental and consumer products industries and to governments. The company operates through a number of subsidiaries, such as VRL Laboratories in the United States, Institut Nehring GmbH in Germany, Agfirst Bay of Plenty, a fruit maturity testing laboratory in New Zealand, and Megalab SA, a clinical diagnostic laboratory in Spain. The company is active through Ahma Group, Villapharma, Exova's environment testing laboratories in Eastern Canada, ASL analises ambientais in Brazil, MVZ fur Laboratoriumsmedizin am Hygiene-Institut Gmbh, Alphora Research, Genoma Laboratory Group, Ana Laboratories Inc, Lifecodexx AG, Gatc Biotech AG, Japan Analytical Chemistry Consultants Co. Ltd. (''Jacc''), Tsing Hua and Ecopro Research K.K. (''Ecopro'') and Craft Technologies.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 24 Oct 1997
- Employees
- 51,516
- Website
- eurofins.com ↗
Leadership
Pay as last reported
- Dr. Gilles MartinChairman of the Board, Chief Executive Officer€5.2m
- Mrs. Valerie HanoteExecutive Director€435,000
- Mr. Pascal RakovskyLead Non-Executive Independent Director€96,300
- Dr. Yves-Loic MartinNon-Executive Director, since 2022€34,000
- Mrs. Patrizia LuchettaNon-Executive Independent Director€71,067
- Ms. Erica MonfardiniNon-Executive Independent Director€37,734
- Mr. Ivo RauhNon-Executive Independent Director€56,600
- Ms. Evie RoosNon-Executive Independent Director€67,300
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 90
- Environment
- 99
- Social
- 99
- Governance
- 71
- Direct emissions (scope 1)
- 61,790 t
- Energy emissions (scope 2)
- 149,493 t
- Value chain emissions (scope 3)
- 290,440 t
- Women in the workforce
- 57%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Eurofins Scientific SE is recognized as an innovative market leader in the field of bio-analytical testing services. The company has a strong track record of developing cutting-edge technologies and solutions, providing them with a competitive advantage over their peers.
- Eurofins operates a vast network of laboratories and offices across the globe, allowing them to serve a wide range of customers in various industries. This extensive global presence enables them to tap into diverse markets and leverage economies of scale.
Weaknesses
- Eurofins relies on external suppliers for certain key materials and technologies. This dependence may pose challenges in terms of cost, quality control, and supply chain management. Any disruptions in the supply chain could negatively impact the company's operations.
- Eurofins Scientific SE operates in a complex industry with diverse testing requirements and regulatory frameworks. Managing this level of complexity requires a high degree of expertise and resources. Any lapses in operational efficiency may result in delays and increased costs.
Opportunities
- The global demand for bio-analytical testing services is expected to grow in the coming years due to factors such as increased regulatory requirements, rising consumer awareness, and advancements in technology. Eurofins can capitalize on this trend by expanding its service offerings and geographic reach.
- Eurofins has the opportunity to expand its presence in emerging markets where demand for testing services is projected to experience significant growth. By establishing strategic partnerships and investing in infrastructure, the company can gain a strong foothold in these promising markets.
Threats
- The bio-analytical testing services industry is highly competitive, with several global and local players vying for market share. Eurofins faces the threat of aggressive pricing strategies, technological advancements by competitors, and the potential entry of new disruptive players.
- Eurofins operates in a regulatory environment that is subject to frequent changes and stringent standards. Compliance with evolving regulations and maintaining necessary accreditations can be demanding and time-consuming, potentially impacting the company's ability to deliver timely and cost-effective services.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.